Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

Maximilian Stahl; Michelle DeVeaux; Pau Montesinos; Raphaël Itzykson; Ellen K Ritchie; Mikkael A Sekeres; John Barnard; Nikolai A Podoltsev; Andrew Brunner; Rami S Komrokji; Vijaya R Bhatt; Aref Al-Kali; Thomas Cluzeau; Valeria Santini; Gail J Roboz; Pierre Fenaux; Mark Litzow; Amir T Fathi; Sarah Perreault; Tae Kon Kim; Thomas Prebet; Norbert Vey; Vivek Verma; Ulrich Germing; Juan Bergua; Josefina Serrano; Steven D Gore; Amer M Zeidan

doi:10.1080/10428194.2018.1468893

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

Leuk Lymphoma. 2019 Jan;60(1):246-249. doi: 10.1080/10428194.2018.1468893. Epub 2018 Jul 2.

Authors

Maximilian Stahl¹, Michelle DeVeaux², Pau Montesinos³, Raphaël Itzykson⁴, Ellen K Ritchie⁵, Mikkael A Sekeres⁶, John Barnard⁶, Nikolai A Podoltsev¹, Andrew Brunner⁷, Rami S Komrokji⁸, Vijaya R Bhatt⁹, Aref Al-Kali¹⁰, Thomas Cluzeau¹¹, Valeria Santini¹², Gail J Roboz⁵, Pierre Fenaux⁴, Mark Litzow¹⁰, Amir T Fathi⁷, Sarah Perreault¹³, Tae Kon Kim¹, Thomas Prebet¹, Norbert Vey¹⁴, Vivek Verma⁹, Ulrich Germing¹⁵, Juan Bergua¹⁶, Josefina Serrano¹⁷, Steven D Gore¹, Amer M Zeidan¹

Affiliations

¹ a Department of Internal Medicine, Section of Hematology, Yale University School of Medicine , New Haven , CT, USA.
² b Department of Biostatistics, Yale School of Public Health , New Haven , CT, USA.
³ c Department of Medicine , University of Valencia, Hospital Universitario y Politécnico La Fe , Valencia, CIBERONC, Instituto III , Madrid , Spain.
⁴ d Department of Hematology/Oncology, Saint-Louis Hospital, University of Paris 7 , France.
⁵ e Division of Hematology and Oncology, Weill Cornell Medicine and The New York Presbyterian Hospital , New York , NY , USA.
⁶ f Leukemia Program Cleveland Clinic , Cleveland , OH , USA.
⁷ g Massachusetts General Hospital Cancer Center Harvard Medical School , Boston , MA , USA.
⁸ h Department of Malignant Hematology , Moffitt Cancer Center and Research Institute , Tampa , FL , USA.
⁹ i Division of Hematology/Oncology, University of Nebraska Medical Center , Omaha , NE , USA.
¹⁰ j Mayo Clinic , Rochester , MN , USA.
¹¹ k Cote d'Azur University, Nice Sophia Antipolis University, CHU of Nice , Nice , France.
¹² l Division of Hematology , University of Florence , Florence , Italy.
¹³ m Department of Pharmacy , Yale New Haven Hospital , New Haven , CT , USA.
¹⁴ n Department of Hematology , Institut Paoli Calmettes , Marseille , France.
¹⁵ o Department of Hematology , Oncology and Clinical Immunology , Heinrich-Heine-University Duesseldorf , Duesseldorf , Germany.
¹⁶ p Hospital San Pedro Alcántara , Cáceres , Spain.
¹⁷ q Division of Hematology/Oncology, University Hospital Reina Sofia , Cordoba , Spain.

PMID: 29963936
DOI: 10.1080/10428194.2018.1468893

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Drug Resistance, Neoplasm
Female
Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myeloid, Acute / mortality
Leukemia, Myeloid, Acute / pathology
Leukemia, Myeloid, Acute / therapy*
Male
Middle Aged
Neoplasm Recurrence, Local / mortality
Neoplasm Recurrence, Local / pathology
Neoplasm Recurrence, Local / therapy*
Prognosis
Retrospective Studies
Risk Assessment / methods
Risk Factors
Survival Analysis
Transplantation, Homologous
Treatment Outcome
Young Adult